Electra Therapeutics: Gordon reports 473K-share buys

Voting and investment power over the funds’ shares is exercised through an OrbiMed Advisors LLC management committee that includes Gordon, W. Carter Neild and Geoffrey C. Hsu.

Available on EDGAR 11/05/2026 - 05:48 PM EST Accepted by SEC EDGAR 11/05/2026 - 05:47 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Electra Therapeutics, Inc. (ETRA) director and 10% owner Carl L. Gordon reported 10 common-stock purchase transactions involving 472,571 shares from November 3 through November 5, 2026, at per-share prices of $7.07, $7.31, $7.78, $7.84 and $7.88. OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P. held the shares directly. Gordon and related entities disclaim beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 472,571 shares

Net Buy 10 txns

Insider GORDON CARL L

Role Director, 10% Owner

Bought 472,571 shs ($3.61M)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F3	30,891	$7.31	$226K
Purchase	Common Stock F2, F3	125,200	$7.31	$915K
Purchase	Common Stock F1, F3	9,267	$7.78	$72K
Purchase	Common Stock F2, F3	37,100	$7.78	$289K
Purchase	Common Stock F1, F3	5,000	$7.07	$35K
Purchase	Common Stock F2, F3	20,000	$7.07	$141K
Purchase	Common Stock F1, F3	24,313	$7.84	$191K
Purchase	Common Stock F2, F3	97,800	$7.84	$767K
Purchase	Common Stock F1, F3	24,400	$7.88	$192K
Purchase	Common Stock F2, F3	98,600	$7.88	$777K

Holdings After Transaction: Common Stock — 2,136,979 shares (Indirect, See footnotes)

Footnotes (3)

1. F1. These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.
2. F2. These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
3. F3. Each of the Reporting Person, OrbiMed Advisors, GP VII and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Key Figures

Shares purchased: 472,571 shares Purchase: 30,891 shares at $7.31 per share Purchase: 125,200 shares at $7.31 per share +2 more

5 metrics

Shares purchased 472,571 shares 10 purchase transactions from November 3 through November 5, 2026

Purchase 30,891 shares at $7.31 per share OrbiMed Private Investments VII, LP, November 5, 2026

Purchase 125,200 shares at $7.31 per share OrbiMed Genesis Master Fund, L.P., November 5, 2026

Purchase 24,313 shares at $7.84 per share OrbiMed Private Investments VII, LP, November 3, 2026

Purchase 98,600 shares at $7.88 per share OrbiMed Genesis Master Fund, L.P., November 3, 2026

Key Terms

beneficial ownership, voting power, investment power, pecuniary interest

4 terms

beneficial ownership regulatory

"may be deemed to have beneficial ownership over such securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

voting power regulatory

"may be deemed to have voting power"

Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.

investment power regulatory

"may be deemed to have voting power and investment power"

pecuniary interest technical

"except to the extent of its pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ETRA shares were purchased in transactions reported by Carl L. Gordon?

The reported transactions cover 472,571 shares in 10 purchases from November 3 through November 5, 2026, at per-share prices of $7.07, $7.31, $7.78, $7.84 and $7.88. The shares were held directly by OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P.; no Rule 10b5-1 plan is reported.

Which entities held the ETRA shares reported by Carl L. Gordon?

OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P. held the shares directly. OrbiMed Advisors LLC exercises voting and investment power through a management committee comprising Carl L. Gordon, W. Carter Neild and Geoffrey C. Hsu; each committee member disclaims beneficial ownership of shares held by the funds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GORDON CARL L

(Last) (First) (Middle)

C/O ELECTRA THERAPEUTICS, INC.

230 E GRAND AVENUE, SUITE S-100

(Street)

SOUTH SAN FRANCISCO NEW YORK 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Electra Therapeutics, Inc. [ ETRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/03/2026		P		24,313	A	$7.84	5,151,204	I	See footnotes(1)(3)
Common Stock	11/03/2026		P		97,800	A	$7.84	1,856,079	I	See footnotes(2)(3)
Common Stock	11/03/2026		P		24,400	A	$7.88	5,175,604	I	See footnotes(1)(3)
Common Stock	11/03/2026		P		98,600	A	$7.88	1,954,679	I	See footnotes(2)(3)
Common Stock	11/04/2026		P		9,267	A	$7.78	5,184,871	I	See footnotes(1)(3)
Common Stock	11/04/2026		P		37,100	A	$7.78	1,991,779	I	See footnotes(2)(3)
Common Stock	11/04/2026		P		5,000	A	$7.07	5,189,871	I	See footnotes(1)(3)
Common Stock	11/04/2026		P		20,000	A	$7.07	2,011,779	I	See footnotes(2)(3)
Common Stock	11/05/2026		P		30,891	A	$7.31	5,220,762	I	See footnotes(1)(3)
Common Stock	11/05/2026		P		125,200	A	$7.31	2,136,979	I	See footnotes(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.

2. These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.

3. Each of the Reporting Person, OrbiMed Advisors, GP VII and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

	/s/ Carl L. Gordon	11/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)